IMPORTANCE: A lack of neuroinhibitory function may result in unopposed excitotoxic neuronal damage in amyotrophic lateral sclerosis (ALS). OBJECTIVE: To determine whether there are reductions in γ-aminobutyric acid (GABA) levels and elevations in glutamate-glutamine (Glx) levels in selected brain regions of patients with ALS by use of proton magnetic resonance spectroscopy. DESIGN: Case-control study using short echo time and GABA-edited proton magnetic resonance spectroscopy at 3 T with regions of interest in the left motor cortex, left subcortical white matter, and pons; data analyzed using logistic regression, t tests, and Pearson correlations; and post hoc analyses performed to investigate differences between riluzole-naive and riluzole-treated patients with ALS. SETTING: Tertiary referral center. PARTICIPANTS: Twenty-nine patients with ALS and 30 age- and sex-matched healthy controls. EXPOSURE: Fifteen patients were taking 50 mg of riluzole twice a day as part of their routine clinical care for ALS. MAIN OUTCOMES AND MEASURES: Levels of GABA, Glx, choline (a marker of cell membrane turnover), creatine (a marker of energy metabolism), myo-inositol (a marker of glial cells), and N-acetylaspartate (a marker of neuronal integrity). RESULTS: Patients with ALS had significantly lower levels of GABA in the motor cortex than did healthy controls (P < .01). Patients with ALS also had significantly lower levels of N-acetylaspartate in the motor cortex (P < .01), subcortical white matter (P < .05), and pons (P < .01) and higher levels of myo-inositol in the motor cortex (P < .001) and subcortical white matter (P < .01) than did healthy controls. Riluzole-naive patients with ALS had higher levels of Glx than did riluzole-treated patients with ALS (P < .05 for pons and motor cortex) and healthy controls (P < .05 for pons and motor cortex). Riluzole-naive patients with ALS had higher levels of creatine in the motor cortex (P < .001 for both comparisons) and subcortical white matter (P ≤ .05 for both comparisons) than did riluzole-treated patients with ALS and healthy controls. Riluzole-naive patients with ALS had higher levels of N-acetylaspartate in the motor cortex than did riluzole-treated patients with ALS (P < .01). CONCLUSIONS AND RELEVANCE: There are reduced levels of GABA in the motor cortex of patients with ALS. There are elevated levels of Glx in riluzole-naive patients with ALS compared with riluzole-treated patients with ALS and healthy controls. These results point to an imbalance between excitatory and inhibitory neurotransmitters as being important in the pathogenesis of ALS and an antiglutamatergic basis for the effects of riluzole, although additional research efforts are needed.
IMPORTANCE: A lack of neuroinhibitory function may result in unopposed excitotoxic neuronal damage in amyotrophic lateral sclerosis (ALS). OBJECTIVE: To determine whether there are reductions in γ-aminobutyric acid (GABA) levels and elevations in glutamate-glutamine (Glx) levels in selected brain regions of patients with ALS by use of proton magnetic resonance spectroscopy. DESIGN: Case-control study using short echo time and GABA-edited proton magnetic resonance spectroscopy at 3 T with regions of interest in the left motor cortex, left subcortical white matter, and pons; data analyzed using logistic regression, t tests, and Pearson correlations; and post hoc analyses performed to investigate differences between riluzole-naive and riluzole-treated patients with ALS. SETTING: Tertiary referral center. PARTICIPANTS: Twenty-nine patients with ALS and 30 age- and sex-matched healthy controls. EXPOSURE: Fifteen patients were taking 50 mg of riluzole twice a day as part of their routine clinical care for ALS. MAIN OUTCOMES AND MEASURES: Levels of GABA, Glx, choline (a marker of cell membrane turnover), creatine (a marker of energy metabolism), myo-inositol (a marker of glial cells), and N-acetylaspartate (a marker of neuronal integrity). RESULTS:Patients with ALS had significantly lower levels of GABA in the motor cortex than did healthy controls (P < .01). Patients with ALS also had significantly lower levels of N-acetylaspartate in the motor cortex (P < .01), subcortical white matter (P < .05), and pons (P < .01) and higher levels of myo-inositol in the motor cortex (P < .001) and subcortical white matter (P < .01) than did healthy controls. Riluzole-naive patients with ALS had higher levels of Glx than did riluzole-treated patients with ALS (P < .05 for pons and motor cortex) and healthy controls (P < .05 for pons and motor cortex). Riluzole-naive patients with ALS had higher levels of creatine in the motor cortex (P < .001 for both comparisons) and subcortical white matter (P ≤ .05 for both comparisons) than did riluzole-treated patients with ALS and healthy controls. Riluzole-naive patients with ALS had higher levels of N-acetylaspartate in the motor cortex than did riluzole-treated patients with ALS (P < .01). CONCLUSIONS AND RELEVANCE: There are reduced levels of GABA in the motor cortex of patients with ALS. There are elevated levels of Glx in riluzole-naive patients with ALS compared with riluzole-treated patients with ALS and healthy controls. These results point to an imbalance between excitatory and inhibitory neurotransmitters as being important in the pathogenesis of ALS and an antiglutamatergic basis for the effects of riluzole, although additional research efforts are needed.
Authors: Jose Luis Nieto-Gonzalez; Jakob Moser; Martin Lauritzen; Thomas Schmitt-John; Kimmo Jensen Journal: Cereb Cortex Date: 2010-07-19 Impact factor: 5.357
Authors: Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing Journal: Lancet Date: 2011-02-04 Impact factor: 79.321
Authors: M Cosottini; G Donatelli; M Costagli; E Caldarazzo Ienco; D Frosini; I Pesaresi; L Biagi; G Siciliano; M Tosetti Journal: AJNR Am J Neuroradiol Date: 2015-12-17 Impact factor: 3.825
Authors: Mark Mikkelsen; Peter B Barker; Pallab K Bhattacharyya; Maiken K Brix; Pieter F Buur; Kim M Cecil; Kimberly L Chan; David Y-T Chen; Alexander R Craven; Koen Cuypers; Michael Dacko; Niall W Duncan; Ulrike Dydak; David A Edmondson; Gabriele Ende; Lars Ersland; Fei Gao; Ian Greenhouse; Ashley D Harris; Naying He; Stefanie Heba; Nigel Hoggard; Tun-Wei Hsu; Jacobus F A Jansen; Alayar Kangarlu; Thomas Lange; R Marc Lebel; Yan Li; Chien-Yuan E Lin; Jy-Kang Liou; Jiing-Feng Lirng; Feng Liu; Ruoyun Ma; Celine Maes; Marta Moreno-Ortega; Scott O Murray; Sean Noah; Ralph Noeske; Michael D Noseworthy; Georg Oeltzschner; James J Prisciandaro; Nicolaas A J Puts; Timothy P L Roberts; Markus Sack; Napapon Sailasuta; Muhammad G Saleh; Michael-Paul Schallmo; Nicholas Simard; Stephan P Swinnen; Martin Tegenthoff; Peter Truong; Guangbin Wang; Iain D Wilkinson; Hans-Jörg Wittsack; Hongmin Xu; Fuhua Yan; Chencheng Zhang; Vadim Zipunnikov; Helge J Zöllner; Richard A E Edden Journal: Neuroimage Date: 2017-07-14 Impact factor: 6.556
Authors: Aifang Cheng; Teng Zhao; Kai-Hei Tse; Hei-Man Chow; Yong Cui; Liwen Jiang; Shengwang Du; Michael M T Loy; Karl Herrup Journal: Proc Natl Acad Sci U S A Date: 2017-12-26 Impact factor: 11.205
Authors: Samaira Younis; Casper E Christensen; Mark B Vestergaard; Ulrich Lindberg; Daniel Tolnai; Olaf B Paulson; Henrik Bw Larsson; Anders Hougaard; Messoud Ashina Journal: J Cereb Blood Flow Metab Date: 2020-05-19 Impact factor: 6.200
Authors: Eric C Porges; Adam J Woods; Richard A E Edden; Nicolaas A J Puts; Ashley D Harris; Huaihou Chen; Amanda M Garcia; Talia R Seider; Damon G Lamb; John B Williamson; Ronald A Cohen Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-01